Replimune Competitors
| REPL Stock | USD 11.66 0.20 1.69% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Replimune competition on your existing holdings.
Replimune |
Replimune Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Replimune and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Replimune and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Replimune Group does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Replimune Stock performing well and Replimune Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Replimune's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NUVL | 2.12 | (0.21) | 0.00 | (0.39) | 0.00 | 3.54 | 12.24 | |||
| VTYX | 4.04 | (0.53) | 0.00 | (0.48) | 0.00 | 6.94 | 35.02 | |||
| ASND | 2.38 | 0.39 | 0.16 | 0.27 | 2.29 | 5.55 | 18.15 | |||
| UTHR | 1.39 | (0.25) | 0.00 | (1.01) | 0.00 | 2.52 | 15.73 | |||
| NVCT | 3.78 | 0.97 | 0.26 | 69.72 | 3.62 | 9.96 | 26.68 | |||
| LYRA | 2.81 | (0.01) | 0.00 | (0.16) | 0.00 | 5.56 | 25.31 | |||
| KRON | 1.71 | (0.05) | 0.00 | (0.22) | 0.00 | 3.23 | 12.10 | |||
| GOSS | 4.60 | 1.26 | 0.23 | 0.79 | 4.64 | 9.84 | 36.67 | |||
| KURA | 2.30 | (0.41) | 0.00 | (0.55) | 0.00 | 4.48 | 13.72 | |||
| PTGX | 2.79 | 0.36 | 0.25 | (0.39) | 2.51 | 3.48 | 49.42 |
Cross Equities Net Income Analysis
Compare Replimune Group and related stocks such as Nuvalent, Ventyx Biosciences, and Ascendis Pharma AS Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.3 M) | (73.3 M) | (126.2 M) | (260.8 M) | (247.7 M) |
| VTYX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (28.5 M) | (78.4 M) | (108 M) | (193 M) | (135.1 M) | (141.9 M) |
| ASND | 1.2 M | 1.2 M | 1.2 M | 4.1 M | (9.7 M) | (32.9 M) | (68.5 M) | (123.9 M) | (130.1 M) | (218 M) | (419 M) | (383.6 M) | (583.2 M) | (481.4 M) | (378.1 M) | (359.2 M) |
| UTHR | (12.8 M) | 217.9 M | 304.4 M | 174.6 M | 340.1 M | 651.6 M | 713.7 M | 417.9 M | 589.2 M | (104.5 M) | 514.8 M | 475.8 M | 727.3 M | 984.8 M | 1.2 B | 1.3 B |
| NVCT | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (12.9 M) | (18.8 M) | (22.3 M) | (19 M) | (19.9 M) |
| LYRA | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (16.1 M) | (22 M) | (42.4 M) | (55.3 M) | (62.7 M) | (56.4 M) | (53.6 M) |
| KRON | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (15.4 M) | (64.1 M) | (149.1 M) | (129.3 M) | (112.7 M) | (101.4 M) | (106.5 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.8 M) | (147 M) | (180.8 M) | (251.6 M) | (249.1 M) | (240.2 M) | (179.8 M) | (161.8 M) | (169.9 M) |
| KURA | (33.6 K) | (22.4 K) | (27 K) | (27.3 K) | (11 M) | (22.6 M) | (27.6 M) | (35.4 M) | (60.4 M) | (63.1 M) | (89.4 M) | (129.9 M) | (136.1 M) | (152.6 M) | (174 M) | (165.3 M) |
| PTGX | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (14.9 M) | (37.2 M) | (37 M) | (38.9 M) | (77.2 M) | (66.2 M) | (122.6 M) | (123.4 M) | (79 M) | 275.2 M | 288.9 M |
| MRUS | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (21.2 M) | (25.3 M) | (49.7 M) | (87.7 M) | (27.8 M) | (55.2 M) | (85.5 M) | (66.8 M) | (131.2 M) | (154.9 M) | (215.3 M) | (204.6 M) |
| AVTE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (9 M) | (23 M) | (51.5 M) | (75.5 M) | (68 M) | (64.6 M) |
| KROS | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (12.3 M) | (45.4 M) | (58.7 M) | (104.7 M) | (153 M) | (187.4 M) | (178 M) |
| SNDX | (10 M) | (10 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (318.8 M) | (302.8 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (71.9 M) | (177.8 M) | (168.9 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.2 M) | (27.1 M) | (49.5 M) | (72.9 M) | (106.7 M) | (160 M) | (214.5 M) | (298.4 M) | (283.5 M) |
| NAMS | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (36.7 M) | (21.1 M) | (176.9 M) | (241.6 M) | (229.5 M) |
| PRTC | (11.1 M) | (11.1 M) | (11.1 M) | (4.3 M) | (41.6 M) | (39.4 M) | (48.8 M) | 30.9 M | (43.7 M) | 421.1 M | 4.6 M | (62.7 M) | (37.1 M) | (65.7 M) | (75.6 M) | (71.8 M) |
Replimune Group and related stocks such as Nuvalent, Ventyx Biosciences, and Ascendis Pharma AS Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Replimune Group financial statement analysis. It represents the amount of money remaining after all of Replimune Group operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Replimune Competitive Analysis
The better you understand Replimune competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Replimune's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Replimune's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Replimune Competition Performance Charts
Five steps to successful analysis of Replimune Competition
Replimune's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Replimune Group in relation to its competition. Replimune's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Replimune in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Replimune's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Replimune Group, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Replimune position
In addition to having Replimune in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Replimune Correlation with its peers. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.